Certara, Inc. (NASDAQ:CERT) Position Increased by Sei Investments Co.

Sei Investments Co. increased its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 2.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,137,612 shares of the company's stock after buying an additional 28,809 shares during the quarter. Sei Investments Co. owned about 0.71% of Certara worth $12,116,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of CERT. Kopion Asset Management LLC boosted its holdings in Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock worth $5,918,000 after acquiring an additional 175,005 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Certara by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock valued at $5,660,000 after purchasing an additional 15,739 shares during the period. Vontobel Holding Ltd. purchased a new position in shares of Certara in the fourth quarter valued at $1,295,000. Barclays PLC grew its holdings in Certara by 198.3% during the 3rd quarter. Barclays PLC now owns 70,525 shares of the company's stock valued at $825,000 after purchasing an additional 46,880 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in Certara during the 4th quarter worth $148,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Price Performance

Shares of Certara stock traded down $0.45 on Thursday, hitting $9.78. The company had a trading volume of 3,404,404 shares, compared to its average volume of 1,056,440. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.18. The company has a market cap of $1.57 billion, a PE ratio of -48.90, a PEG ratio of 9.29 and a beta of 1.60. The business has a 50-day simple moving average of $12.22 and a 200-day simple moving average of $11.42. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Remove Ads

Analysts Set New Price Targets

Several brokerages have recently weighed in on CERT. TD Cowen assumed coverage on Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Barclays increased their target price on Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Finally, Stephens reaffirmed an "overweight" rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Certara presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.